Shenzhen Weiguang Biological Products , Ltd. EBIT

As of the most recent data (September 2026), 002880.SZ shows a EBIT of $220M. That compares with $290M in the prior-year period — down 24.1% year over year. That is below the Healthcare sector average of $99B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 002880.SZ's EBIT is now $220M (was $290M) — a 24.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Shenzhen Weiguang Biological Products , Ltd. is outperforming or lagging.

The Healthcare sector average EBIT is about $99B. Shenzhen Weiguang Biological Products , Ltd. is at $220M, which is lower that average. That is roughly 99.8% below the sector mean. Use the comparison chart on this page to see how 002880.SZ stacks up against individual peers as well.

Tracking 002880.SZ's ebit over time shows whether Shenzhen Weiguang Biological Products , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $220M That compares with $290M in the prior-year period — down 24.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Shenzhen Weiguang Biological Products , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $220M) with ownership activity and broader fundamentals.